JOP20220124A1 - مشتقات 1، 2، 4-أوكساديازول كناهضات مستقبلات الكبد x - Google Patents
مشتقات 1، 2، 4-أوكساديازول كناهضات مستقبلات الكبد xInfo
- Publication number
- JOP20220124A1 JOP20220124A1 JOP/2022/0124A JOP20220124A JOP20220124A1 JO P20220124 A1 JOP20220124 A1 JO P20220124A1 JO P20220124 A JOP20220124 A JO P20220124A JO P20220124 A1 JOP20220124 A1 JO P20220124A1
- Authority
- JO
- Jordan
- Prior art keywords
- liver
- receptor agonists
- oxadiazole derivatives
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يتم في هذه الوثيقة توفير مركبات وتركيبات صيدلانية مفيدة في علاج خلل وظيفي في غدة ميبوميوس (غدة الجفن) (MGD)، والتي تشتمل على إعطاء خاضع للعلاج في حاجةٍ إليها كمية فعالة علاجياً من مركبٍ من الصيغة (I) أو مركبٍ من الصيغة (I’)، أو تركيبة صيدلانية تم وصفها في هذه الوثيقة.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962940061P | 2019-11-25 | 2019-11-25 | |
US202063106293P | 2020-10-27 | 2020-10-27 | |
PCT/IB2020/061053 WO2021105857A1 (en) | 2019-11-25 | 2020-11-23 | 1,2,4-oxadiazole derivatives as liver x receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20220124A1 true JOP20220124A1 (ar) | 2023-01-30 |
Family
ID=73654860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2022/0124A JOP20220124A1 (ar) | 2019-11-25 | 2020-11-23 | مشتقات 1، 2، 4-أوكساديازول كناهضات مستقبلات الكبد x |
Country Status (19)
Country | Link |
---|---|
US (2) | US11427586B2 (ar) |
EP (1) | EP4065228A1 (ar) |
JP (1) | JP2023503320A (ar) |
KR (1) | KR20220106778A (ar) |
CN (1) | CN114746149A (ar) |
AU (1) | AU2020394597B2 (ar) |
BR (1) | BR112022009942A2 (ar) |
CA (1) | CA3157657A1 (ar) |
CL (1) | CL2022001323A1 (ar) |
CO (1) | CO2022006645A2 (ar) |
CR (1) | CR20220227A (ar) |
EC (1) | ECSP22040362A (ar) |
IL (1) | IL291958A (ar) |
JO (1) | JOP20220124A1 (ar) |
MX (1) | MX2022006151A (ar) |
PE (1) | PE20221785A1 (ar) |
TW (1) | TW202132289A (ar) |
UY (1) | UY38964A (ar) |
WO (1) | WO2021105857A1 (ar) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240238305A1 (en) * | 2021-05-20 | 2024-07-18 | Novartis Ag | Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione |
WO2022249006A1 (en) * | 2021-05-24 | 2022-12-01 | Novartis Ag | Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists |
KR20240059836A (ko) | 2022-10-28 | 2024-05-08 | (주)케이메디켐 | 신규 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201120016A (en) | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
WO2015187840A2 (en) * | 2014-06-03 | 2015-12-10 | Duke University | Methods and formulations for treatment of ocular disorders |
US20200188297A1 (en) | 2018-12-13 | 2020-06-18 | eyeNOS, Inc. | LXR Agonist in Topical Ophthalmic Formulation for Treatment of Dry-Eye Disorder |
-
2020
- 2020-11-20 UY UY0001038964A patent/UY38964A/es unknown
- 2020-11-23 WO PCT/IB2020/061053 patent/WO2021105857A1/en active Application Filing
- 2020-11-23 JO JOP/2022/0124A patent/JOP20220124A1/ar unknown
- 2020-11-23 PE PE2022000828A patent/PE20221785A1/es unknown
- 2020-11-23 JP JP2022529931A patent/JP2023503320A/ja active Pending
- 2020-11-23 KR KR1020227020461A patent/KR20220106778A/ko unknown
- 2020-11-23 EP EP20817082.9A patent/EP4065228A1/en active Pending
- 2020-11-23 TW TW109140930A patent/TW202132289A/zh unknown
- 2020-11-23 AU AU2020394597A patent/AU2020394597B2/en not_active Expired - Fee Related
- 2020-11-23 MX MX2022006151A patent/MX2022006151A/es unknown
- 2020-11-23 BR BR112022009942A patent/BR112022009942A2/pt unknown
- 2020-11-23 IL IL291958A patent/IL291958A/en unknown
- 2020-11-23 CA CA3157657A patent/CA3157657A1/en active Pending
- 2020-11-23 CN CN202080081467.7A patent/CN114746149A/zh active Pending
- 2020-11-23 US US17/101,510 patent/US11427586B2/en active Active
- 2020-11-23 CR CR20220227A patent/CR20220227A/es unknown
-
2022
- 2022-05-19 CO CONC2022/0006645A patent/CO2022006645A2/es unknown
- 2022-05-19 EC ECSENADI202240362A patent/ECSP22040362A/es unknown
- 2022-05-19 CL CL2022001323A patent/CL2022001323A1/es unknown
- 2022-06-06 US US17/805,487 patent/US20220340573A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114746149A (zh) | 2022-07-12 |
BR112022009942A2 (pt) | 2022-08-09 |
KR20220106778A (ko) | 2022-07-29 |
MX2022006151A (es) | 2022-08-02 |
UY38964A (es) | 2021-06-30 |
CL2022001323A1 (es) | 2023-03-24 |
WO2021105857A1 (en) | 2021-06-03 |
US20220340573A1 (en) | 2022-10-27 |
CA3157657A1 (en) | 2021-06-03 |
TW202132289A (zh) | 2021-09-01 |
ECSP22040362A (es) | 2022-06-30 |
AU2020394597A1 (en) | 2022-06-02 |
IL291958A (en) | 2022-06-01 |
EP4065228A1 (en) | 2022-10-05 |
US20220064164A1 (en) | 2022-03-03 |
CR20220227A (es) | 2022-06-15 |
US11427586B2 (en) | 2022-08-30 |
PE20221785A1 (es) | 2022-11-22 |
JP2023503320A (ja) | 2023-01-27 |
CO2022006645A2 (es) | 2022-05-31 |
AU2020394597B2 (en) | 2024-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20220124A1 (ar) | مشتقات 1، 2، 4-أوكساديازول كناهضات مستقبلات الكبد x | |
MX2023007192A (es) | Inhibidores de prmt5. | |
CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
MX2020008173A (es) | Combinacion de un agente antimuscarinico o de uno anticolinergico y acido lipoico, y sus usos. | |
MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
MX2010001189A (es) | Derivados de naftiridina como modulares del canal de potasio. | |
PH12020551501A1 (en) | Oxadiazole transient receptor potential channel inhibitors | |
TW200806299A (en) | Treatment of pain | |
BR0314126A (pt) | Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio | |
BRPI0518781A2 (pt) | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto | |
MX2023007140A (es) | Compuestos farmaceuticos. | |
BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
MX2024006094A (es) | Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. | |
CO5200778A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis | |
HRP20231037T1 (hr) | Deuterirani spojevi za upotrebu u liječenju raka | |
IL276194B2 (en) | Pharmaceutical compounds or preparations containing them for use in the treatment of pain | |
MX2020002429A (es) | Compuestos para reducir la viscosidad de las formulaciones biologicas. | |
MX2023011377A (es) | Derivados de ciclobutilo 1,3-sustituidos y sus usos. | |
MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
WO2020141828A3 (en) | Anticancer compositions comprising immune checkpoint inhibitors | |
MX2024002409A (es) | Terapias contra el cancer. | |
MX2022002339A (es) | Derivados de alfa-d-galactopiranosido. | |
JOP20220082A1 (ar) | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
MX2020008413A (es) | Composiciones para la prevencion o tratamiento de la uveitis. |